Clinical trials: Arts
Assisted Reproductive Technology, Controlled Ovarian Hyperstimulation
Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures
To explore the optimal effective daily dose of BG2109 to suppress premature luteinizing hormone (LH) surge during COH in female subjects undergoing ART procedures.
- Trial name
- NCT05738382
- Testing
- BG2109, Cetrorelix
- Where
- 10 sites in China
- Volunteers
- 240 people
- Sponsor
- Bio Genuine (Shanghai) Biotech Co., Ltd.
Dental Caries
Survival Rate and Cost-effectiveness of Conventional vs ART Restorations in a School Setting
This study will investigate the performance and cost-effectiveness of glass-ionomer restorations placed in school children in an outreach setting in rural areas in South Africa over a 2-year period, when placed using either ART…
- Trial name
- NCT05766696
- Testing
- Atraumatic Restorative Treatment (ART), Conventional Cavity Preparation
- Where
- South Africa
- Volunteers
- 200 people
- Sponsor
- DMG Dental Material Gesellschaft mbH
Progesterone Supplementation in Women Undergoing ART
Clinical Safety Study of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology Procedures
The purpose of the study is to assess the safety of Progesterone Vaginal Ring (PVR) in women undergoing fresh embryo transfer (ART).
- Trial name
- SARA (NCT03565211)
- Testing
- Progesterone vaginal ring
- Where
- 15 sites in United States
- Volunteers
- 352 people
- Sponsor
- Ferring Pharmaceuticals
HIV
An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy
To test the hypothesis that AGT103-T cells therapy will allow HIV positive individual to reduce, modify or eliminate antiretroviral therapy.
- Trial name
- NCT05540964
- Testing
- Antiretroviral Therapy Interruption(ATI)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- American Gene Technologies International Inc.
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
The goal of this clinical study is to learn more about the impact of cobicistat (COBI) (P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and strong cytochrome P450 enzyme [CYP]3A inhibitor), voriconazole (VOR)…
- Trial name
- NCT05458102
- Testing
- Vesatolimod, Cobicistat, Voriconazole
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
HIV-1
A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)
This study will evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral therapy (ART) activity of islatravir (MK-8591) monotherapy in ART-naive, human immunodeficiency virus-1 (HIV-1) infected participants.
- Trial name
- NCT02217904
- Testing
- 1 mg islatravir, 2 mg islatravir, 10 mg islatravir
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV, Human Immunodeficiency Virus
An Extension of Protocol PRO 140_CD01 Study
This is an extension of Protocol PRO 140_CD 01 to further evaluate the long-term suppression of HIV-1 replication following substitution of stable combination antiretroviral therapy with a PRO 140 (Monoclonal CCR5 antibody)…
- Trial name
- NCT02355184
- Testing
- PRO 140 350mg weekly subcutaneous (SC) injection.
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- CytoDyn, Inc.
HIV Infections
Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients
The primary purpose of the study is to investigate the safety and efficacy of KP-1461 given every 12 hours for 124 days to HIV+ patients who have failed multiple antiretroviral regimens.
- Trial name
- NCT00504452
- Testing
- KP-1461
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 27 people
- Sponsor
- Koronis Pharmaceuticals.
HIV-1 Infection
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
During the course of HIV infection the number of CD4 cells decreases, resulting in a reduced immunological response and ultimately immune deficiency.
- Trial name
- IMID (NCT01704781)
- Testing
- Lenalidomide, Vacc-4X, rhuGM-CSF
- Where
- 4 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Bionor Immuno AS
Loss of Face Volume
Evaluation of the Efficacy and Safety of Three Injectable Hyaluronic Acid-based Fillers: Art Filler® Fine Lines, Art Filler® Universal and Art Filler® Lips
The function of injectable fillers for the treatment of dermal contour deformities is to smooth dermal depressions formed by the loss of volume and the aging process.
- Trial name
- AF4 (NCT04647513)
- Testing
- Intradermal injection (superficial dermis for Art Filler Fine Lines / moderately deep to deep dermis for Art Filler Universal and Art Filler Lips)
- Where
- France
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Laboratoires FILLMED
Infertility
Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)
Development of multiple follicles and pregnancy in ovulatory women undergoing controlled ovarian stimulation as part of an assisted reproductive technology (ART) cycle.
- Trial name
- CLARA (NCT04163458)
- Testing
- MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL, MENOPUR powder and solvent for solution for injection, 75 IU
- Where
- 20 sites in United States
- Volunteers
- 405 people
- Sponsor
- Ferring Pharmaceuticals
Assisted Reproduction
Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)
This is a multicentre, open-label, dose-finding, phase 2 study that will recruit approximately 90 female subjects undergoing COH for in vitro fertilization (IVF) or intracytoplasmic single sperm injection (ICSI).
- Trial name
- NCT07236476
- Testing
- LY01021
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Luye Pharma Group Ltd.
HIV Infections
Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV
The purpose of this study is to examine the ability of AGS-004 to control HIV-1 replication and to determine if HIV-1 immunotherapy made with dendritic cells is safe and well tolerated, to determine if immunotherapy increases the…
- Trial name
- NCT00672191
- Testing
- AGS-004
- Where
- 12 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Argos Therapeutics
Stress Regulation and Well-being in Non-clinical Contexts
The Concert Therapy for Stress Regulation in a Non-Clinical Adult Population
The Concert Therapy is a non-clinical, art based well-being intervention designed to support stress regulation through a structured, concert like experience.
- Trial name
- TCT-RCT (NCT07430631)
- Testing
- The Concert Therapy, Active Control: Relaxing Music and Quiet Rest
- Where
- United Kingdom
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Behnam Khodarahmi
Infertility, Recurrent Pregnancy Loss
Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis
We propose to perform a clinical randomized trial to evaluate the effect of blastocyst biopsy and whole chromosome analysis by Next Generation Sequencing (NGS) in comparison to standard Assisted Reproductive Technologies (ART)…
- Trial name
- NCT01946945
- Testing
- Next Generation Sequencing after Blastocyst biopsy
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Reprogenetics
HIV Infections, AIDS
DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy
The purpose of this study is to evaluate whether a therapy with an all once daily regimen of efavirenz (EFV), didanosine (ddI)-EC and lamivudine (3TC) leads to improved outcomes, as measured by viral load, CD4 counts, adherence…
- Trial name
- NCT00116415
- Testing
- efavirenz; didanosine EC; lamivudine
- Where
- 9 sites in United States
- Volunteers
- 65 people
- Sponsor
- Bristol-Myers Squibb
Infertility
Clinical Study of Clinical Efficacy and Tolerability of hMG-IBSA s.c.in Women Undergoing COH in an ART Programme (IVF).
Multicenter, prospective, randomized, investigator blind, controlled clinical trial. Two parallel groups, one receiving the test drug hMG (hMG-IBSA, IBSA Institut Biochimique sa) and the other the reference drug hMG (Menopur…
- Trial name
- NCT00335894
- Testing
- hMG-IBSA
- Where
- 2 sites in Italy
- Volunteers
- 144 people
- Sponsor
- IBSA Institut Biochimique SA
HIV Infections
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
Study ING116529 is a multicenter, randomized, study with an initial 7 day placebo- controlled, functional monotherapy phase to quantify the antiviral activity attributable to dolutegravir (DTG) in HIV-1 infected, ART-experienced…
- Trial name
- VIKING-4 (NCT01568892)
- Testing
- Dolutegravir 50 mg twice daily
- Where
- 25 sites in United States
- Volunteers
- 30 people
- Sponsor
- ViiV Healthcare
Fracture, Infection, Human Immunodeficiency Virus
Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status
This US population-based study will explore the incidence of and risks for fracture among adults with and without human immunodeficiency virus (HIV) infection.
- Trial name
- NCT01077557
- Testing
- No Antiretroviral (ARV) Drug Exposure, Any Antiretroviral (ARV) Drug Exposure
- Volunteers
- 1 people
- Sponsor
- ViiV Healthcare
Infertility
Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)
This is a Phase 2, interventional, prospective, multi-center, randomized, assessor-blind, active-comparator, dose-finding study to evaluate a new investigational long-acting follicle stimulating hormone (FSH) in infertile women…
- Trial name
- NCT00505752
- Testing
- AS900672-Enriched 50 microgram (mcg), AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg
- Where
- United States
- Volunteers
- 520 people
- Sponsor
- Merck KGaA, Darmstadt, Germany